Log in to search using one of your social media accounts:

 

More Laboratory Tests Performed at Major Teaching Hospitals
More tests per day for bacterial pneumonia, cellulitis at major teaching versus nonteaching hospitals (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 14, 2017 Category: Respiratory Medicine Tags: Family Medicine, Geriatrics, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pathology, Pulmonology, Journal, Source Type: news

Paratek reports positive data from Phase III trial of omadacycline
Paratek Pharmaceuticals has reported positive safety and efficacy data from a Phase III clinical trial (OPTIC) of its investigational antibiotic, omadacycline, for community-acquired bacterial pneumonia (CABP). (Source: Drug Development Technology)
Source: Drug Development Technology - October 8, 2017 Category: Pharmaceuticals Source Type: news

US FDA grants priority review status to Allergan ’s sNDA for Avycaz
The US Food and Drug Administration (FDA) has granted priority review status for Allergan ’s supplemental New Drug Application (sNDA) for Avycaz (ceftazidime and avibactam) to treat hospital-acquired bacterial pneumonia / ventilator-associated bacteri… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 2, 2017 Category: Pharmaceuticals Source Type: news

Nabriva's Pneumonia Drug Succeeds in Late-stage Trial Nabriva's Pneumonia Drug Succeeds in Late-stage Trial
Nabriva Therapeutics Plc has reported that its experimental antibiotic for community-acquired bacterial pneumonia (CABP) met the main goal of a late-stage study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Nabriva's pneumonia drug succeeds in late-stage trial, shares soar
(Reuters) - Nabriva Therapeutics Plc shares more than doubled in premarket trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia met the main goal of a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - September 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Nabriva's pneumonia drug meets main goal in late-stage study
(Reuters) - Nabriva Therapeutics Plc said on Monday its experimental treatment for community-acquired bacterial pneumonia met the main goal in a late-stage study, sending its shares up more than 70 percent in premarket trading. (Source: Reuters: Health)
Source: Reuters: Health - September 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Researchers identify changes in lung cells following infections
When people develop a respiratory infection, recovery from their illness leaves behind an immunological memory that influences how they will respond to later infections. In a new study, researchers demonstrate for the first time that recovery from bacterial pneumonia changes the tissue that was infected, seeding the lungs with immune cells called resident memory T (TRM) cells. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 17, 2017 Category: Science Source Type: news

Researchers identify changes in lung cells following infections
(Boston University Medical Center) When people develop a respiratory infection, recovery from their illness leaves behind an immunological memory that influences how they will respond to later infections. In a new study, researchers demonstrate for the first time that recovery from bacterial pneumonia changes the tissue that was infected, seeding the lungs with immune cells called resident memory T (TRM) cells. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 17, 2017 Category: Infectious Diseases Source Type: news

Antibiotic developer's stock soars 23% thanks to positive study data
Paratek Pharmaceuticals, a Boston biotech company that has rapidly expanded its presence in the Philadelphia suburbs, saw its stock price soar by 23 percent Tuesday after posting positive results from late-stage testing of its lead new drug candidate. The study showed omadacycline, its experimental oral and IV antibiotic, met all the clinical trial's primary and secondary endpoints in treating patients with community-acquired bacterial pneumonia. Paratek's stock closed up 23 percent at $22.85 per… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 4, 2017 Category: Biotechnology Authors: John George Source Type: news

Antibiotic developer's stock soars 23% thanks to positive study data
Paratek Pharmaceuticals, a Boston biotech company that has rapidly expanded its presence in the Philadelphia suburbs, saw its stock price soar by 23 percent Tuesday after posting positive results from late-stage testing of its lead new drug candidate. The study showed omadacycline, its experimental oral and IV antibiotic, met all the clinical trial's primary and secondary endpoints in treating patients with community-acquired bacterial pneumonia. Paratek's stock closed up 23 percent at $22.85 per… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 4, 2017 Category: American Health Authors: John George Source Type: news

Paratek's Phase III trial of omadacycline shows positive outcome in CABP treatment
US-based biopharmaceutical firm Paratek Pharmaceuticals has reported positive top-line results from its Phase III clinical trial of omadacycline to treat community-acquired bacterial pneumonia (CABP) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - April 3, 2017 Category: Pharmaceuticals Source Type: news

Beating deadly pneumonia with hormones
Researchers have identified a hormone that helps fight off a severe form of bacterial pneumonia, and that discovery may offer a simple way to help vulnerable patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 29, 2017 Category: Science Source Type: news

Discovery may help patients beat deadly pneumonia
(University of Virginia Health System) Researchers have identified a hormone that helps fight off a severe form of bacterial pneumonia, and that discovery may offer a simple way to help vulnerable patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2017 Category: Global & Universal Source Type: news

Why Pneumonia Often Strikes Older Adults
Former President George H.W. Bush was hospitalized on Jan. 14 following a bout of pneumonia, CNN reported Jan. 18. In addition, Bush’s wife, former first lady Barbara Bush, was admitted to the hospital as a precaution because she was experiencing “fatigue and coughing,” according to CNN. The 41st president turned 92 last summer, and Barbara Bush is 91. Why does pneumonia often strike older adults? [27 Devastating Infectious Diseases] One reason is that a person’s immunity declines after age 50, “so it wouldn’t be surprising if someone who’s over 90 would have a reduced immunity,&rd...
Source: Healthy Living - The Huffington Post - January 19, 2017 Category: Consumer Health News Source Type: news

A possible treatment for severe sepsis undergoes clinical test
EU-funded project SEPCELL will conduct a clinical trial of a stem cell treatment for patients with severe sepsis caused by a severe form of community-acquired bacterial pneumonia. The trial is one of a series of steps in assessing whether the treatment is safe and efficacious for patients with this life-threatening disease. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - January 5, 2017 Category: Research Source Type: news

FDA Rejects Cempra's Pneumonia Antibiotic
The U.S. FDA has rejected Cempra's antibiotic, solithromycin, for treating community-acquired bacterial pneumonia (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 29, 2016 Category: Pharmaceuticals Source Type: news

FDA rejects Cempra's antibiotic for pneumonia, shares sink
(Reuters) - Cempra Inc said on Thursday the U.S. Food and Drug Administration had rejected its antibiotic for community-acquired bacterial pneumonia (CABP), citing inadequate data on the drug's impact on the liver and manufacturing issues. (Source: Reuters: Health)
Source: Reuters: Health - December 29, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Advisory Committee Votes That Efficacy Results of Cempra's Solithromycin Outweigh Risks for Community-Acquired Bacterial Pneumonia
CHAPEL HILL, N.C., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 4, 2016 Category: Drugs & Pharmacology Source Type: news

Clinton campaign releases new health information
Hillary Clinton's campaign released additional medical information Wednesday after questions about her health intensified in the wake of her pneumonia diagnosis late last week. She was diagnosed with mild, non-contagious bacterial pneumonia, her docto... (Source: WDSU.com - Health)
Source: WDSU.com - Health - September 14, 2016 Category: Consumer Health News Source Type: news

Read The Letter Hillary Clinton's Doctor Wrote About The Presidential Nominee's Health
Hillary Clinton’s doctor penned a letter Wednesday with more information about the Democratic presidential nominee’s health. The letter comes as Clinton recovers from a bout of pneumonia. Clinton’s physician, Dr. Lisa Bardack, said the presidential hopeful “is recovering well with antibiotics and rest.” Below, the full text of Dr. Bardack’s letter on Clinton’s health: This letter is a summary update on Hillary Rodham Clinton’s health since the release of my previous medical statement in July 2015. Mrs. Clinton has been seen by me regularly this year for routine car...
Source: Healthy Living - The Huffington Post - September 14, 2016 Category: Consumer Health News Source Type: news

Medical News Today: Bacterial Pneumonia: Get the Facts
This article looks at its causes, symptoms, diagnosis, and treatment. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 26, 2016 Category: Consumer Health News Tags: Infectious Diseases / Bacteria / Viruses Source Type: news

Solithera (solithromycin) for the Treatment of Community-Acquired Bacterial Pneumonia
Solithera (solithromycin) is a next-generation macrolide antibiotic developed by Cempra as a treatment for community-acquired bacterial pneumonia. (Source: Drug Development Technology)
Source: Drug Development Technology - August 7, 2016 Category: Pharmaceuticals Source Type: news

Legionnaires' Disease Making a Comeback
Older Americans are at higher risk for the bacterial pneumonia. (Source: U.S. News - Health)
Source: U.S. News - Health - July 6, 2016 Category: Consumer Health News Authors: Lisa Esposito Source Type: news

FDA accepts Cempra's application for next-gen pneumonia treatment
Prabhavathi Fernandes, the CEO of Chapel Hill-based drug developer Cempra (Nasdaq: CEMP) will circle Dec. 27 and Dec. 28 with a big red marker on her calendar. Those are the deadlines for the U.S. Food and Drug Administration to rule on Cempra’s application for approval for a next-generation pneumonia treatment. The FDA accepted Cempra’s applications for solithromycin, which Cempra has given the name Solithera, a treatment for treatment for community-acquired bacterial pneumonia (CABP) that… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 5, 2016 Category: Biotechnology Authors: Jason deBruyn Source Type: news

Cempra Announces FDA Acceptance of Solithera New Drug Applications in the Treatment of Community-Acquired Bacterial Pneumonia
CHAPEL HILL, N.C., July 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 5, 2016 Category: Drugs & Pharmacology Source Type: news

Bacterial Pneumonia
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 24, 2016 Category: Journals (General) Source Type: news

Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
Label Now Includes New Data on Use of TEFLARO in Pediatric Patients 2 Months of Age to Less than 18 Years of Age with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP) TEFLARO is the First Bran... Biopharmaceuticals, FDAAllergan, ABSSSI, TEFLARO, MRSA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 31, 2016 Category: Pharmaceuticals Source Type: news

Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
CHAPEL HILL, N.C., May 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 1, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
Application Seeks to Expand Label with New Data on Pediatric Patients 2 Months of Age and Older with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP) DUBLIN, Feb. 16, 2016 -- (Healthcare Sale... Biopharmaceuticals, FDAAllergan, TEFLARO, ceftaroline, MRSA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 16, 2016 Category: Pharmaceuticals Source Type: news

Novel Antibiotic Shows Promise for Community-Acquired Pneumonia (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Oral solithromycin is noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia, according to an industry-funded, phase 3 trial published … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 8, 2016 Category: Primary Care Source Type: news

Can Antibiotics Do More Harm Than Good Treating Colds?
BOSTON (CBS) — ‘Tis the season for colds, coughs and sore throats and this is a good time to remind ourselves that antibiotics are not only useless for most of these symptoms, but could do more harm than good. Antibiotics can cause a rash, stomach upset, or a yeast infection and in the long-term could lead to more bacterial resistance, not only in the community but also in your own body so that when you really need them, they will be less likely to work. Antibiotics (WBZ-TV) So the only time you should ask for or expect a prescription for an antibiotic from your physician is if you have a bacterial infection li...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 18, 2016 Category: Consumer Health News Authors: mouellette2015 Tags: Health Healthwatch Local News Seen On WBZ-TV Syndicated Local Watch Listen Antibiotics Dr. Mallika Marshall Treating Colds Source Type: news

Scientists 'see' detailed make-up of deadly toxin for the first time
An exciting advance provides hope for developing novel potential method of treating pneumococcal diseases such as bacterial pneumonia, meningitis and septicaemia. A team of researchers uses a technique called X-ray crystallography to see the individual atoms of the toxin. World Health Organization (WHO) estimated that more than 1.6 million people every year die from pneumococcal infections, including more than 800,000 children under 5 years old. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 24, 2015 Category: Science Source Type: news

Scientists 'see' detailed make-up of deadly toxin for the first time
(University of Leicester) Exciting advance provides hope for developing novel potential method of treating pneumococcal diseases such as bacterial pneumonia, meningitis and septicaemia. University of Leicester uses technique called X-ray crystallography at Diamond Light Source, the UK's national synchrotron science facility, to see the individual atoms of the toxin. World Health Organization (WHO) estimated that more than 1.6 million people every year die from pneumococcal infections, including more than 800,000 children under 5 years old. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 24, 2015 Category: Infectious Diseases Source Type: news

Get the flu vaccine, reduce your risk of death
Last year was a lousy year for the flu vaccine. Hospitalizations for flu hit a nine-year high, and the vaccine prevented flu in only 23% of all recipients, compared with 50% to 60% of recipients in prior years. Why does the flu vaccine work well in some winters and not others? The flu vaccine primes the immune system to attack two proteins on the surface of the influenza A virus, hemagglutinin (H) and neuraminidase (N). Different flu strains have different combinations of these proteins — for example, the strains targeted by recent flu vaccines are H3N2 and H1N1. Unfortunately, the influenza virus is microbiology&rsq...
Source: New Harvard Health Information - September 15, 2015 Category: Consumer Health News Authors: John Ross, MD, FIDSA Tags: Cold and Flu Vaccines Flu Shot flu vaccine Source Type: news

Cempra’s solithromycin receives FDA fast track designation to treat CABP
Clinical-stage pharmaceutical firm Cempra has obtained fast track designation from the US Food and Drug Administration (FDA) for solithromycin intravenous (IV) and capsules to treat community acquired bacterial pneumonia (CABP). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 20, 2015 Category: Pharmaceuticals Source Type: news

Liver plays role in pneumonia, sepsis susceptibility
(Boston University Medical Center) New evidence highlights the importance of the liver in immunity against bacterial pneumonia. The study is the first of its kind to directly show such a link between liver-produced molecules and pneumonia susceptibility during sepsis. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 30, 2015 Category: Infectious Diseases Source Type: news

Links between household air pollution, lung infections examined, including pneumonia
Scientists have come a step closer to understanding why people exposed to household air pollution (HAP) are at higher risk of lung infections such as pneumonia and tuberculosis. Three billion people worldwide are exposed to HAP from the fuels they burn to cook, light and heat with at home. Frequently, charcoal, wood and food waste are burned and generate high concentrations of smoke particles. This exposure is associated with increased risk of pneumonia, particularly in low and middle income countries where bacterial pneumonia is the biggest cause of infant mortality. This risk is well known, but the reasons are not. (Sour...
Source: ScienceDaily Headlines - May 8, 2015 Category: Science Source Type: news

RSV infection may be associated with higher risk for bacterial pneumonia
Two common and sometimes dangerous respiratory diseases, a viral one caused by respiratory syncytial virus (RSV), and a bacterial one caused by Streptococcus pneumoniae may be linked, suggests a new study. Scientists analyzed hospitalization data to investigate a possible association between RSV and pneumonia in young children, and found that infection with RSV may increase the risk of pneumonia. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 6, 2015 Category: Science Source Type: news

RSV infection may be associated with higher risk for bacterial pneumonia
(PLOS) Two common and sometimes dangerous respiratory diseases, a viral one caused by respiratory syncytial virus (RSV), and a bacterial one caused by Streptococcus pneumoniae may be linked, suggests a study published in this week's PLOS Medicine. Daniel Weinberger, from Yale University School of Public Health, and colleagues, analyzed hospitalization data to investigate a possible association between RSV and pneumonia in young children, and found that infection with RSV may increase the risk of pneumonia. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 6, 2015 Category: Infectious Diseases Source Type: news

Cempra Announces Positive Topline Phase 3 Clinical Results for Oral Solithromycin in the Treatment of Community Acquired Bacterial Pneumonia
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - January 5, 2015 Category: Pharmaceuticals Source Type: news

Cempra's solithromycin meets primary and secondary objectives in Phase III trial
US-based pharmaceutical firm Cempra has reported positive topline results from a global, pivotal Phase III clinical trial of solithromycin oral capsules (Solitaire-Oral) in the treatment of patients with community acquired bacterial pneumonia (CABP). (Source: Drug Development Technology)
Source: Drug Development Technology - January 5, 2015 Category: Pharmaceuticals Source Type: news

Researchers look to exploit females' natural resistance to infection
Researchers have linked increased resistance to bacterial pneumonia in female mice to an enzyme activated by the female sex hormone estrogen. An international team of scientists has shown that increased resistance to bacterial pneumonia in female mice is linked to the enzyme nitric oxide synthase 3 (NOS3). They also show that this enzyme is ultimately activated by the release of the female sex hormone estrogen. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 15, 2014 Category: Science Source Type: news

Researchers look to exploit females' natural resistance to infection
(eLife ) Researchers have linked increased resistance to bacterial pneumonia in female mice to an enzyme activated by the female sex hormone estrogen. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 15, 2014 Category: Global & Universal Source Type: news

Scientists Spot How Bacterial Pneumonia Damages the Heart
Title: Scientists Spot How Bacterial Pneumonia Damages the HeartCategory: Health NewsCreated: 9/19/2014 12:35:00 PMLast Editorial Review: 9/22/2014 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - September 22, 2014 Category: Respiratory Medicine Source Type: news

Scientists Spot How Bacterial Pneumonia Damages the Heart
A vaccine, and the right antibiotic, may guard against a direct attack on heart cells, researchers say (Source: WebMD Health)
Source: WebMD Health - September 19, 2014 Category: Consumer Health News Source Type: news

Scientists Spot How Bacterial Pneumonia Damages the Heart
A vaccine, and the right antibiotic, may guard against a direct attack on heart cells, researchers say Source: HealthDay Related MedlinePlus Pages: Bacterial Infections, Heart Diseases, Pneumonia (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 19, 2014 Category: Consumer Health News Source Type: news

Scientists Spot How Bacterial Pneumonia Damages the Heart
A vaccine, and the right antibiotic, may guard against a direct attack on heart cells, researchers say (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 19, 2014 Category: Respiratory Medicine Authors: webmaster at doctorslounge.com Tags: Cardiology, Pulmonology, Research, News, Source Type: news

How pneumonia bacteria can compromise heart health
Bacterial pneumonia in adults carries an elevated risk for adverse cardiac events (such as heart failure, arrhythmias, and heart attacks) that contribute substantially to mortality -- but how the heart is compromised has been unclear. A study now demonstrates that Streptococcus pneumoniae, the bacterium responsible for most cases of bacterial pneumonia, can invade the heart and cause the death of heart muscle cells. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 18, 2014 Category: Science Source Type: news

How pneumonia bacteria can compromise heart health
(PLOS) Bacterial pneumonia in adults carries an elevated risk for adverse cardiac events (such as heart failure, arrhythmias, and heart attacks) that contribute substantially to mortality -- but how the heart is compromised has been unclear. A study published on Sept. 18 in PLOS Pathogens now demonstrates that Streptococcus pneumoniae, the bacterium responsible for most cases of bacterial pneumonia, can invade the heart and cause the death of heart muscle cells. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 18, 2014 Category: Infectious Diseases Source Type: news